View source for 5-HT2B receptor

{{DISPLAYTITLE:5-HT<sub>2B</sub> receptor}}
{{PBB|geneid=3357}}
'''5-hydroxytryptamine (serotonin) receptor 2B''', also known as '''HTR2B''', is a [[5-HT2 receptor|5-HT<sub>2</sub> receptor]], but also denotes the human [[gene]] encoding it.<ref name="entrez_ 3357">{{cite web | title = Entrez Gene: HTR<sub>2B</sub> 5-hydroxytryptamine (serotonin) receptor 2B| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=3357| accessdate = }}</ref><ref name="pmid8143856">{{cite journal | author = Schmuck K, Ullmer C, Engels P, Lübbert H | title = Cloning and functional characterization of the human 5-HT<sub>2B</sub> serotonin receptor | journal = FEBS Lett. | volume = 342 | issue = 1 | pages = 85–90 | year = 1994 | month = March | pmid = 8143856 | doi = 10.1016/0014-5793(94)80590-3| url = http://linkinghub.elsevier.com/retrieve/pii/0014-5793(94)80590-3 | issn = }}</ref>

==Function==
The 5-HT<sub>2</sub> receptors (of which the 5-HT<sub>2B</sub> receptor is a subtype) mediate many of the central and peripheral physiologic functions of [[serotonin]]. Cardiovascular effects include contraction of blood vessels and shape changes in platelets; central nervous system effects include neuronal sensitization to tactile stimuli and mediation of some of the effects of [[amphetamine|phenylisopropylamine]] [[hallucinogen]]s.

The 5-HT<sub>2B</sub> receptor subtype is involved in:
* CNS: [[presynaptic inhibition]], behavioural effects<ref name="pmid18337424">{{cite journal | author = Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L | title = Serotonin 5-HT<sub>2B</sub> receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro | journal = J. Neurosci. | volume = 28 | issue = 11 | pages = 2933–40 | year = 2008 | month = March | pmid = 18337424 | doi = 10.1523/JNEUROSCI.5723-07.2008 | url = | issn = }}</ref>
* Vascular: pulmonary [[vasoconstriction]]<ref name="pmid12244304">{{cite journal | author = Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L | title = Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension | journal = Nat. Med. | volume = 8 | issue = 10 | pages = 1129–35 | year = 2002 | month = October | pmid = 12244304 | doi = 10.1038/nm764 | url = | issn = }}</ref>
* Cardiac: The 5-HT<sub>2B</sub> receptor regulates cardiac structure and functions as demonstrated by the abnormal cardiac development observed in 5-HT<sub>2B</sub> receptor null mice.<ref name="pmid11413089">{{cite journal | author = Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, György K, Matz R, Andriantsitohaina R, Manivet P, Launay JM, Maroteaux L | title = Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function | journal = Circulation | volume = 103 | issue = 24 | pages = 2973–9 | year = 2001 | month = June | pmid = 11413089 | doi = | url = http://circ.ahajournals.org/cgi/content/abstract/103/24/2973 | issn = }}</ref> The 5-HT<sub>2B</sub> receptor stimulation can also lead to pathological proliferation of cardiac valves fibroblasts,<ref name="pmid18511249">{{cite journal | author = Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N | title = 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats | journal = Exp. Toxicol. Pathol. | volume = 60 | issue = 4-5 | pages = 253–62 | year = 2008 | month = August | pmid = 18511249 | doi = 10.1016/j.etp.2008.03.005 | url = | issn = }}</ref> which with chronic overstimulation of 5-HT<sub>2B</sub> can lead to a severe valvulopathy. Moreover, 5-HT<sub>2B</sub> receptors were recently shown to be overexpressed in human failing heart and antagonists of 5-HT<sub>2B</sub> receptors were uncovered  to prevent both angiotensin II or beta-adrenergic agonist-induced pathological cardiac hypertrophy in mouse.<ref name="pmid15302781">{{cite journal | author = Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L | title = Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts | journal = Circulation | volume = 110 | issue = 8 | pages = 969–74 | year = 2004 | month = August | pmid = 15302781 | doi = 10.1161/01.CIR.0000139856.20505.57 | url = | issn = }}</ref><ref name="pmid18591460">{{cite journal | author = Monassier L, Laplante MA, Jaffré F, Bousquet P, Maroteaux L, de Champlain J | title = Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice | journal = Hypertension | volume = 52 | issue = 2 | pages = 301–7 | year = 2008 | month = August | pmid = 18591460 | doi = 10.1161/HYPERTENSIONAHA.107.105551 | url = | issn = }}</ref><ref name="pmid19023134">{{cite journal | author = Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L | title = Serotonin and Angiotensin Receptors in Cardiac Fibroblasts Coregulate Adrenergic-Dependent Cardiac Hypertrophy | journal = Circ. Res. | volume = 104| issue = 1| pages = 113| year = 2008 | month = November | pmid = 19023134 | doi = 10.1161/CIRCRESAHA.108.180976 | url = | issn = }}</ref>

* [[Serotonin transporter]]: 5-HT<sub>2B</sub> receptors regulate serotonin release via the serotonin transporter, and are important both to normal physiological regulation of serotonin levels in blood plasma,<ref name="pmid16461587">{{cite journal | author = Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, Launay JM, Maroteaux L | title = Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine(2B) receptors in mice | journal = J. Pharmacol. Exp. Ther. | volume = 317 | issue = 2 | pages = 724–31 | year = 2006 | month = May | pmid = 16461587 | doi = 10.1124/jpet.105.098269 | url = | issn = }}</ref> and with the abnormal acute serotonin release produced by drugs such as [[MDMA]].<ref name="pmid18337424">{{cite journal | author = Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L | title = Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro | journal = J. Neurosci. | volume = 28 | issue = 11 | pages = 2933–40 | year = 2008 | month = March | pmid = 18337424 | doi = 10.1523/JNEUROSCI.5723-07.2008 | url = | issn = }}</ref>

==Ligands==
As of 2009, few highly selective 5-HT<sub>2B</sub> receptor ligands have been discovered, although numerous potent non-selective compounds are known, particularly agents with concomitant 5-HT<sub>2C</sub> binding. Research in this area has been limited due to the cardiotoxicity of 5HT<sub>2B</sub> agonists, and the lack of clear therapeutic application for 5HT<sub>2B</sub> antagonists, but there is still a need for selective ligands for scientific research.<ref name="Schuhmacher">{{cite paper  | author = Schuhmacher M  | title = [Chiral arylmethoxytryptamines as 5-HT<sub>2B</sub>-receptor antagonists: synthesis, analysis and in-vitro pharmacology] (German)  | version = Ph.D. Dissertation | publisher =  University of Regensburg   | year = 2007 | pages = pages 6–17 | url = http://www.opus-bayern.de/uni-regensburg/volltexte/2008/796/pdf/Dissertation_Schumacher.pdf | accessdate = 2008-08-11 }}</ref> 

===Agonists===
;Selective
* [[BW-723C86]]:<ref name="pmid10498829">{{cite journal |author=Porter RH, Benwell KR, Lamb H, ''et al.'' |title=Functional characterization of agonists at recombinant human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors in CHO-K1 cells |journal=Br. J. Pharmacol. |volume=128 |issue=1 |pages=13–20 |year=1999 |pmid=10498829 |pmc=1571597 |doi=10.1038/sj.bjp.0702751 |url=}}</ref> fair functional subtype selectivity; almost full agonist. Anxiolytic ''in vivo''.<ref name="pmid9886683">{{cite journal | author = Kennett GA, Trail B, Bright F | title = Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated | journal = Neuropharmacology | volume = 37 | issue = 12 | pages = 1603–10 | year = 1998 | month = December | pmid = 9886683 | doi = 10.1016/S0028-3908(98)00115-4  | url =  | issn = }}</ref> 
* [[Ro60-0175]] <ref name="pmid10498829"/> functionally selective over 5-HT<sub>2A</sub>, potent agonist at both 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> 
* [[VER-3323]]: selective for 5-HT<sub>2B/2C</sub> over 5-HT<sub>2A</sub>
* [[α-Methyl-5-HT]] - moderately selective over 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>

;Non-selective
* [[MDMA]] (Ecstasy)<ref name="MDx">{{cite journal |author=Setola, Vincent |coauthors=Sandra J Hufeisen, K Jane Grande-Allen, Ivan Vesely, Richard A Glennon, Bruce Blough, Richard B Rothman, Bryan L Roth |title=3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro |journal=Molecular pharmacology |volume=63 |issue=6 |pages=1223&ndash;1229 | date= Jan 7 2003 | doi=10.1124/mol.63.6.1223 |abstract=https://www.researchgate.net/publication/10748715_34-methylenedioxymethamphetamine_%28MDMA_Ecstasy%29_induces_fenfluramine-like_proliferative_actions_on_human_cardiac_valvular_interstitial_cells_in_vitro |pmid=12761331}}</ref>
* [[methylenedioxyamphetamine|MDA]]<ref name="MDx"/>
* [[2,5-Dimethoxy-4-ethoxyamphetamine|MEM]]<ref name="pmid20126400">{{cite journal | author = Ray TS | last2 = Manzoni | first2 = Olivier Jacques | title = Psychedelics and the human receptorome | journal = PLoS ONE | volume = 5 | issue = 2 | pages = e9019 | year = 2010 | pmid = 20126400 | pmc = 2814854 | doi = 10.1371/journal.pone.0009019 | url = }}</ref>
* [[Pergolide]]<ref name="pmid18096760">{{cite journal |author=Görnemann T, Hübner H, Gmeiner P, ''et al.'' |title=Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine<sub>2B</sub> and 5-Hydroxytryptamine<sub>2A</sub> receptors |journal=J. Pharmacol. Exp. Ther. |volume=324 |issue=3 |pages=1136–45 |year=2008 |pmid=18096760 |doi=10.1124/jpet.107.133165}}</ref>
* [[Cabergoline]]
* [[Norfenfluramine]]<ref name="pmid10498829"/> 
* [[Chlorphentermine]]
* [[Aminorex]]
* [[1-(3-Chlorophenyl)piperazine|mCPP]]
* [[Bromo-dragonfly]]
* [[Psilocin]]
* [[DMT]]
* [[5-MeO-DMT]]

===Antagonists===
* [[Sarpogrelate]] (mixed 5-HT<sub>2A</sub> / 5-HT<sub>2B</sub> antagonist)
* [[Lisuride]] (primarily dopamine agonist, but 5-HT<sub>2B</sub> antagonist effects as well)<ref name="pmid16614540">{{cite journal | author = Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, Latté KP, Palla D, Schurad B | title = Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis | journal = Clin Neuropharmacol | volume = 29 | issue = 2 | pages = 80–6 | year = 2006 | pmid = 16614540 | doi = 10.1097/00002826-200603000-00005| url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002826-200603000-00005 | issn = }}</ref>
* [[Tegaserod]] (primarily 5-HT<sub>4</sub> agonist, but also 5-HT<sub>2B</sub> antagonist)<ref>{{cite journal |author=Beattie DT, Smith JA, Marquess D, ''et al.'' |title=The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo |journal=Br. J. Pharmacol. |volume=143 |issue=5 |pages=549–60 |year=2004 |month=November |pmid=15466450 |pmc=1575425 |doi=10.1038/sj.bjp.0705929 |url=}}</ref>
* [[RS-127,445]]:<ref name="pmid10455251">{{cite journal |author=Bonhaus DW, Flippin LA, Greenhouse RJ, ''et al.'' |title=RS-127445: a selective, high affinity, orally bioavailable 5-HT<sub>2B</sub> receptor antagonist |journal=Br. J. Pharmacol. |volume=127 |issue=5 |pages=1075–82 |year=1999 |pmid=10455251 |pmc=1566110 |doi=10.1038/sj.bjp.0702632 |url=}}</ref> high affinity; subtype selective (1000x), selective over at least eight other 5-HTR types; orally bioavailable. 
* [[SDZ SER-082]]: mixed 5-HT<sub>2B/2C</sub> antagonist
* EGIS-7625: high selectivity over 5-HT<sub>2A</sub><ref name="pmid15107597">{{cite journal |author=Kovács A, Gacsályi I, Wellmann J, ''et al.'' |title=Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist |journal=Cardiovasc Drugs Ther |volume=17 |issue=5-6 |pages=427–34 |year=2003 |pmid=15107597 |doi= 10.1023/B:CARD.0000015857.96371.43|url=}}</ref>
* SB-200,646
* [[SB-204,741]]
* SB-206,553: mixed 5-HT<sub>2B</sub> / 5-HT<sub>2C</sub> antagonist and PAM at [[Alpha-7 nicotinic receptor#PAMs|α7 nAChR]]<ref name="pmid19050173">{{cite journal |author=Dunlop J, Lock T, Jow B, ''et al.'' |title=Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide) |journal=J. Pharmacol. Exp. Ther. |volume=328 |issue=3 |pages=766–76 |year=2009 |month=March |pmid=19050173 |doi=10.1124/jpet.108.146514 |url=}}</ref>
* [[SB-215,505]] <ref name="pmid10188965">{{cite journal |author=Reavill C, Kettle A, Holland V, Riley G, Blackburn TP |title=Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist |journal=Br. J. Pharmacol. |volume=126 |issue=3 |pages=572–4 |year=1999 |month=February |pmid=10188965 |pmc=1565856 |doi=10.1038/sj.bjp.0702350 |url=}}</ref>
* SB-228,357
* [[LY-272,015]]

==Possible Applications==
5-HT<sub>2B</sub> antagonists have previously been proposed as treatment for [[migraine]] headaches, and RS-127,445 was trialled in humans up to Phase I for this indication, but development was not continued.<ref>{{cite journal |author=Poissonnet G, Parmentier JG, Boutin JA, Goldstein S |title=The emergence of selective 5-HT 2B antagonists structures, activities and potential therapeutic applications |journal=Mini Rev Med Chem |volume=4 |issue=3 |pages=325–30 |year=2004 |month=March |pmid=15032678 |doi= 10.2174/1389557043487312|url=}}</ref> More recent research has focused on possible application of 5-HT<sub>2B</sub> antagonists as treatments for chronic [[heart disease]].<ref name="pmid19118279">{{cite journal |author=Shyu KG |title=Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure? |journal=Circulation Research |volume=104 |issue=1 |pages=1–3 |year=2009 |month=January |pmid=19118279 |doi=10.1161/CIRCRESAHA.108.191122 |url=}}</ref><ref name="pmid19307114">{{cite journal |author=Moss N, Choi Y, Cogan D, Flegg A, Kahrs A, Loke P, Meyn O, Nagaraja R, Napier S, Parker A, Thomas Peterson J, Ramsden P, Sarko C, Skow D, Tomlinson J, Tye H, Whitaker M |title=A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties |journal=Bioorganic & Medicinal Chemistry Letters |volume=19 |issue=8 |pages=2206–10 |year=2009 |month=April |pmid=19307114 |doi=10.1016/j.bmcl.2009.02.126 |url=}}</ref>

==See also==
* [[5-HT receptor]]

==References==
{{Reflist|2}}

==External links==
* {{cite web | url = http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2322 | title = 5-HT<sub>2B</sub>  | accessdate = | author = | authorlink = | coauthors = | date = | format = | work = IUPHAR Database of Receptors and Ion Channels | publisher = International Union of Basic and Clinical Pharmacology | pages = | language = | archiveurl = | archivedate = | quote = }}

==Further reading==
{{refbegin | 2}}
{{PBB_Further_reading 
| citations = 
*{{cite journal  | author=Raymond JR, Mukhin YV, Gelasco A, ''et al.'' |title=Multiplicity of mechanisms of serotonin receptor signal transduction. |journal=Pharmacol. Ther. |volume=92 |issue= 2-3 |pages= 179–212 |year= 2002 |pmid= 11916537 |doi=10.1016/S0163-7258(01)00169-3  }}
*{{cite journal  | author=Bonhaus DW, Bach C, DeSouza A, ''et al.'' |title=The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. |journal=Br. J. Pharmacol. |volume=115 |issue= 4 |pages= 622–8 |year= 1995 |pmid= 7582481 |doi=  | pmc=1908489  }}
*{{cite journal  | author=Choi DS, Birraux G, Launay JM, Maroteaux L |title=The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2 and 5-HT1D receptors. |journal=FEBS Lett. |volume=352 |issue= 3 |pages= 393–9 |year= 1994 |pmid= 7926008 |doi=10.1016/0014-5793(94)00968-6  }}
*{{cite journal  | author=Kursar JD, Nelson DL, Wainscott DB, Baez M |title=Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. |journal=Mol. Pharmacol. |volume=46 |issue= 2 |pages= 227–34 |year= 1994 |pmid= 8078486 |doi=  }}
*{{cite journal  | author=Schmuck K, Ullmer C, Engels P, Lübbert H |title=Cloning and functional characterization of the human 5-HT2B serotonin receptor. |journal=FEBS Lett. |volume=342 |issue= 1 |pages= 85–90 |year= 1994 |pmid= 8143856 |doi=10.1016/0014-5793(94)80590-3  }}
*{{cite journal  | author=Launay JM, Birraux G, Bondoux D, ''et al.'' |title=Ras involvement in signal transduction by the serotonin 5-HT2B receptor. |journal=J. Biol. Chem. |volume=271 |issue= 6 |pages= 3141–7 |year= 1996 |pmid= 8621713 |doi=10.1074/jbc.271.6.3141  }}
*{{cite journal  | author=Le Coniat M, Choi DS, Maroteaux L, ''et al.'' |title=The 5-HT2B receptor gene maps to 2q36.3-2q37.1. |journal=Genomics |volume=32 |issue= 1 |pages= 172–3 |year= 1996 |pmid= 8786115 |doi= 10.1006/geno.1996.0101 }}
*{{cite journal  | author=Kim SJ, Veenstra-VanderWeele J, Hanna GL, ''et al.'' |title=Mutation screening of human 5-HT(2B)receptor gene in early-onset obsessive-compulsive disorder. |journal=Mol. Cell. Probes |volume=14 |issue= 1 |pages= 47–52 |year= 2000 |pmid= 10722792 |doi= 10.1006/mcpr.1999.0281 }}
*{{cite journal  | author=Manivet P, Mouillet-Richard S, Callebert J, ''et al.'' |title=PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. |journal=J. Biol. Chem. |volume=275 |issue= 13 |pages= 9324–31 |year= 2000 |pmid= 10734074 |doi=10.1074/jbc.275.13.9324  }}
*{{cite journal  | author=Becamel C, Figge A, Poliak S, ''et al.'' |title=Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. |journal=J. Biol. Chem. |volume=276 |issue= 16 |pages= 12974–82 |year= 2001 |pmid= 11150294 |doi= 10.1074/jbc.M008089200 }}
*{{cite journal  | author=Manivet P, Schneider B, Smith JC, ''et al.'' |title=The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis. |journal=J. Biol. Chem. |volume=277 |issue= 19 |pages= 17170–8 |year= 2002 |pmid= 11859080 |doi= 10.1074/jbc.M200195200 }}
*{{cite journal  | author=Borman RA, Tilford NS, Harmer DW, ''et al.'' |title=5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. |journal=Br. J. Pharmacol. |volume=135 |issue= 5 |pages= 1144–51 |year= 2002 |pmid= 11877320 |doi= 10.1038/sj.bjp.0704571  | pmc=1573235 }}
*{{cite journal  | author=Strausberg RL, Feingold EA, Grouse LH, ''et al.'' |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899  | pmc=139241 }}
*{{cite journal  | author=Matsuda A, Suzuki Y, Honda G, ''et al.'' |title=Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. |journal=Oncogene |volume=22 |issue= 21 |pages= 3307–18 |year= 2003 |pmid= 12761501 |doi= 10.1038/sj.onc.1206406 }}
*{{cite journal  | author=Slominski A, Pisarchik A, Zbytek B, ''et al.'' |title=Functional activity of serotoninergic and melatoninergic systems expressed in the skin. |journal=J. Cell. Physiol. |volume=196 |issue= 1 |pages= 144–53 |year= 2003 |pmid= 12767050 |doi= 10.1002/jcp.10287 }}
*{{cite journal  | author=Gerhard DS, Wagner L, Feingold EA, ''et al.'' |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504  | pmc=528928 }}
*{{cite journal  | author=Lin Z, Walther D, Yu XY, ''et al.'' |title=The human serotonin receptor 2B: coding region polymorphisms and association with vulnerability to illegal drug abuse. |journal=Pharmacogenetics |volume=14 |issue= 12 |pages= 805–11 |year= 2005 |pmid= 15608559 |doi=10.1097/00008571-200412000-00003  }}
*{{cite journal  | author=Hillier LW, Graves TA, Fulton RS, ''et al.'' |title=Generation and annotation of the DNA sequences of human chromosomes 2 and 4. |journal=Nature |volume=434 |issue= 7034 |pages= 724–31 |year= 2005 |pmid= 15815621 |doi= 10.1038/nature03466 }}
}}
{{refend}}

{{NLM content}}

{{G protein-coupled receptors}}
{{Cell signaling}}
{{Serotonergics}}

<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
| update_page = yes 
| require_manual_inspection = no 
| update_protein_box = yes
| update_summary = no
| update_citations = yes
}}

[[Category:G protein coupled receptors]]

{{transmembranereceptor-stub}}
[[Category:2Fix]]